Q4 2024 Earnings Call Transcript March 20, 2025 Operator: Hello, and welcome to the Adaptimmune’s Q4 and Full Year 2024 ...

Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its ...

TECELRA ® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achieved Lete-cel on track to initiate rolling BLA ...

Hello, and welcome to the Adaptimmune's Q4 and Full Year 2024 Business Update Conference Call. As a reminder, all participants are in a listen-only mode. The conference is being recorded.

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with ...

1 Department of Pathology, Lu’an hospital of Anhui Medical University, Anhui, China 2 Department of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China ...

SON-1010, an engineered interleukin-12 cytokine, aims to activate the immune system to target tumor cells in sarcoma patients. The SB101 trial's Safety Review Committee found no unexpected toxicities ...

Adaptimmune Therapeutics reported its Q4 2024 financial results, highlighting a product revenue of $1.2 million and projecting a significant revenue increase in Q1 2025. The company is targeting $ ...

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers ...